Board Changes
hVIVO plc
(“hVIVO”, the “Company" or the “Group”)
Board Changes
London, UK – 22 September 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, today announces the following changes to the Board as part of the ongoing evolution of its composition.
- Appointment of Caroline Shaw, CBE as Independent Non-Executive Director, effective from 1 October 2026. Caroline will also serve as Chair of the Remuneration Committee and as a member of the Audit Committee
- Elaine Sullivan to step down as Independent Non-Executive Director, effective from 1 October 2026
Appointment of Caroline Shaw, CBE: Caroline brings more than 30 years’ senior healthcare leadership experience across the NHS, independent healthcare, digital health and life sciences. She has held Chief Executive and board-level roles in both the public and private sectors, with expertise spanning strategy, clinical governance, operational transformation and commercial growth.
Her prior roles include Chief Executive Officer of Evergreen Life where she led a successful turnaround to profitability; Chief Executive Officer of Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust; Chief Operating Officer / Deputy Chief Executive Officer of Nottingham University Hospitals NHS Trust; and Chief Executive Officer of The Christie NHS Foundation Trust.
Resignation of Elaine Sullivan: Concurrently, Elaine Sullivan will step down as an independent Non-Executive Director. Elaine joined the Board of hVIVO (then part of Open Orphan) in November 2020 and has previously served as Senior Independent Director and Chair of the Remuneration Committee.
Shaun Chilton, Non-Executive Chair of hVIVO plc, said: “On behalf of the Board, I would like to thank Elaine for her contribution to hVIVO over the past six years during a period of strategic transformation. We wish her every success for the future.
"We are delighted to welcome Caroline Shaw to the Board. Her extensive clinical, operational and commercial leadership experience will be valuable as we continue to develop hVIVO’s broader, integrated clinical development platform and realise the significant opportunities it has to offer.”
Additional Information on the Board Appointment
The following additional information is provided with regards to the appointment of Caroline Sarah Shaw, aged 59, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
|
Current directorships/partnerships: |
Former directorships/partnerships (within the last five years): |
|
None |
Evergreen Health Solutions Ltd |
|
|
Omnes Group Ltd |
|
|
Omnes Healthcare Ltd |
|
|
Queen Elizabeth Hospital King's Lynn NHS Foundation (Trust) |
Caroline Shaw does not hold any shares or options in the Company. There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
For further information please contact:
|
hVIVO plc |
+44 (0)20 7756 1300 | |||
|
Yamin ‘Mo’ Khan, Chief Executive Officer Susan Stuart, Head of IR and Corporate Communications |
| |||
|
|
| |||
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0)20 7220 0500 | |||
|
Geoff Nash, Callum Davidson, Nigel Birks |
| |||
|
|
| |||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 | |||
|
James Steel, Dr Christopher Golden |
| |||
|
|
| |||
|
Davy (Joint Broker) |
+353 (0) 1 679 6363 | |||
|
Anthony Farrell, Niall Gilchrist |
| |||
|
|
| |||
|
ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson
|
hVIVO@icrhealthcare.com | |||
Notes to Editors
About hVIVO
hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.
The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.
With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.
- Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.
- Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.
- Human Challenge Trials leverages hVIVO’s state-of-the-art quarantine facility in London – the largest of its kind worldwide – to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.
- Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE